C92

Myeloid leukemia

## Clinical Description Myeloid leukemia (C92) represents a diverse group of hematologic malignancies characterized by the clonal expansion and accumulation of abnormal myeloid cells—the precursors of granulocytes, erythrocytes, and megakaryocytes—within the bone marrow and peripheral blood. These neoplastic cells interfere with normal hematopoiesis, leading to severe clinical consequences such as anemia, thrombocytopenia, and neutropenia. The classification of myeloid leukemia under the ICD-10 framework encompasses both acute forms (AML), characterized by rapid progression and immature blasts, and chronic forms (CML), typically marked by a more indolent course and the proliferation of more mature myeloid elements. ### Pathophysiology The pathogenesis of myeloid leukemia involves complex genetic alterations in hematopoietic stem cells. In Acute Myeloid Leukemia (AML), somatic mutations lead to an arrest in cell differentiation and uncontrolled proliferation. Common mutations involve genes such as FLT3, NPM1, and DNMT3A, alongside chromosomal translocations like t(8;21). In Chronic Myeloid Leukemia (CML), the hallmark is the Philadelphia chromosome (Ph+), a translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] resulting in the BCR-ABL1 fusion gene. This gene encodes a constitutively active tyrosine kinase that drives the expansion of the myeloid compartment. ### Clinical Presentation and Diagnosis Patients often present with symptoms related to bone marrow failure. Constitutional symptoms such as night sweats, weight loss, and fever are common. Physical examination may reveal splenomegaly, particularly in CML, or signs of bleeding and infection in AML. Diagnosis is established through peripheral blood smears and bone marrow aspiration and biopsy. Flow cytometry is essential for immunophenotyping to distinguish myeloid from lymphoid lineages. For AML, the World Health Organization (WHO) typically requires a blast count of 20% or more in the marrow or blood, though certain cytogenetic abnormalities allow for a diagnosis regardless of blast percentage. Genetic and molecular profiling is now standard of care to risk-stratify patients and identify targets for therapy. ### Standard of Care Management strategies vary significantly between subtypes. AML often requires intensive induction chemotherapy, traditionally the '7+3' regimen (cytarabine and an anthracycline), followed by consolidation therapy or allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk patients. CML treatment has been transformed by Tyrosine Kinase Inhibitors (TKIs) like imatinib, dasatinib, and nilotinib, which allow many patients to achieve a normal life expectancy. Targeted therapies, such as midostaurin for FLT3-mutated AML or venetoclax for older adults, have recently improved outcomes in previously difficult-to-treat populations.

Clinical Symptoms

  • Persistent fatigue and generalized weakness
  • Fever and frequent, recurrent infections
  • Easy bruising and petechiae
  • Recurrent epistaxis or gingival bleeding
  • Bone and joint pain
  • Unexplained weight loss and anorexia
  • Drenching night sweats
  • Abdominal discomfort or early satiety due to splenomegaly
  • Shortness of breath on exertion
  • Gingival hyperplasia (specifically in monocytic subtypes)

Common Causes

  • Somatic genetic mutations in hematopoietic progenitor cells
  • Ionizing radiation exposure
  • Long-term exposure to benzene or industrial solvents
  • Prior treatment with alkylating agents or topoisomerase II inhibitors (Therapy-related leukemia)
  • Evolution from existing myelodysplastic syndromes (MDS)
  • Evolution from myeloproliferative neoplasms (MPN)
  • Genetic predispositions including Down Syndrome, Fanconi Anemia, and Li-Fraumeni syndrome
  • Tobacco use (associated with increased AML risk)

Documentation & Coding Tips

Distinguish between the specific phases of Chronic Myeloid Leukemia (CML) to ensure correct risk adjustment and code selection.

Example: Patient with BCR-ABL1 positive CML currently in the accelerated phase, presenting with increased peripheral blood blasts (15%). No evidence of blast crisis. The condition is managed with second-generation TKI therapy and remains not in remission. Comorbidities include chronic kidney disease stage 3.

Billing Focus: Documentation must specify the phase (chronic, accelerated, or blast) and BCR-ABL1 status to support code C92.10 through C92.12.

Explicitly state the remission status using standard clinical terminology such as 'in remission', 'in complete remission', or 'in relapse'.

Example: 65-year-old male with Acute Myeloid Leukemia (AML) with inv(16), currently in complete remission following induction and consolidation chemotherapy. Bone marrow biopsy shows no morphologic evidence of leukemia. Follow-up includes molecular monitoring for minimal residual disease.

Billing Focus: The ICD-10-CM sixth character identifies remission status: 0 for not in remission, 1 for in remission, and 2 for in relapse.

Document specific genetic and molecular abnormalities as they now define unique ICD-10-CM categories under C92.

Example: Acute Myeloid Leukemia with NPM1 mutation, not having achieved remission. Cytogenetic analysis confirmed the mutation. Current treatment plan involves intensive chemotherapy with Venetoclax. Patient also has associated pancytopenia due to marrow involvement.

Billing Focus: Identifying the mutation (e.g., NPM1, FLT3, CEBPA) allows for coding under specific subcategories like C92.A0 rather than unspecified AML.

Differentiate between de novo myeloid leukemia and therapy-related myeloid neoplasms.

Example: Patient presents with therapy-related myeloid leukemia (t-ML) following previous treatment for breast cancer with alkylating agents five years ago. Current bone marrow shows 30% blasts. This is a secondary malignancy related to prior antineoplastic therapy.

Billing Focus: Use code C92.60 for acute myeloid leukemia with 11q23-abnormality if applicable, or document if it is therapy-related to ensure secondary malignancy coding rules apply.

Capture all associated cytopenias and systemic complications directly resulting from the myeloid leukemia.

Example: Acute myelomonocytic leukemia, not in remission, complicated by acute febrile neutropenia and thrombocytopenia with mucosal bleeding. Required platelet transfusion and IV piperacillin-tazobactam. Leukemia is the primary diagnosis with complications as secondary codes.

Billing Focus: Ensure secondary codes for neutropenia (D70.1) and thrombocytopenia (D69.6) are linked to the primary leukemia diagnosis to demonstrate medical necessity for high-level E/M.

Relevant CPT Codes

Related Diagnoses

Hierarchy